Bactericidal activity of OPC-67683 against drug-tolerant Mycobacterium tuberculosis

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 5, 2007, Pages 994-998

  Saliu, Oluwabunmi Y ^a   Crismale, Catina ^a   Schwander, Stephan K ^a   Wallis, Robert S ^a,b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b PPD   (United States)

Author keywords

Relapse; Sterilization; Tolerance; Tuberculosis

Indexed keywords

ISONIAZID; OPC 67683; RIFAMPICIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; BACTERIUM ISOLATE; CONCENTRATION RESPONSE; DRUG EXPOSURE; DRUG TOLERANCE; IN VITRO STUDY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; RADIOMETRY;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; MYCOBACTERIUM TUBERCULOSIS; NITROIMIDAZOLES; OXAZOLES; TIME FACTORS;

EID: 35448951418     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm291     Document Type: Article

References (18)

1. O'Brien RJ. Global alliance for-TB drug development. Scientific blueprint for tuberculosis drug development. Tuberculosis 2001; 81: 1-52.
2. Kim KS, Bayer AS. Significance of in-vitro penicillin tolerance in experimental enterococcall endocarditis. J Antimicrob Chemother 1987; 19: 475-85.
3. Tuomanen E. Phenotypic tolerance: The search for β-lactam antibiotics that kill nongrowing bacteria. Rev Infect Dis 1986; 8 Suppl 3: S279-91.
4. Wallis RS, Patil S, Cheon SH et al. Drug tolerance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1999; 43 2600-6.
5. Matsumoto M, Hashizume H, Tomishige T et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006; 3: e466.
6. Silver RF, Li Q, Boom WH et al. Lymphocyte-dependent inhibition of growth of virulent Mycobacterium tuberculosis H37Rv within human monocytes: Requirement for CD4+ T cells in purified protein derivative-positive, but not in purified protein derivative-negative subjects. J Immunol 1998; 160: 2408-17.
7. Mitchison DA. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months [letter]. Am Rev Respir Dis 1993; 147: 1062-3.
8. Wallis RS, Johnson JL. Surrogate markers to assess clinical efficacy of new antituberculous drugs. In: Yew WW, ed. The Development of New Antituberculosis Drugs. Hauppage, NY: Nova Science Publishers, 2006; 95-113.
9. Botha FJ, Sirgel FA, Parkin DP et al. Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis. S Afr Med J 1996; 86: 155-8.
10. Jindani A, Aber VR, Edwards EA et al. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980; 121: 939-49.
11. Kennedy N, Fox R, Kisyombe GM et al. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. Am Rev Respir Dis 1993; 148: 1547-51.
12. Sirgel FA, Botha FJ, Parkin DP et al. The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: A new method of drug assessment. J Antimicrob Chemother 1993; 32: 867-75.
13. Herbert D, Paramasivan CN, Venkatesan P et al. Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampicin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996; 40: 2296-9.
14. Wallis RS. Reconsidering adjuvant immunotherapy for tuberculosis. Clin Infect Dis 2005; 41: 201-8.
15. Dickinson JM, Mitchison DA. Experimental models to explain the high sterilizing activity of rifampicin in the chemotherapy of tuberculosis. Am Rev Respir Dis 1981; 123: 367-71.
16. Karakousis PC, Yoshimatsu T, Lamichhane G et al. Dormancy phenotype displayed by extracellular Mycobacteterium tuberculosis within artificial granulomas in mice. J Exp Med 2004; 200: 647-57.
17. Murugasu-Oei B, Dick T. Bactericidal activity of nitrofurans against growing and dormant Mycobacterium bovis BCG. J Antimicrob Chemother 2000; 46: 917-9.
18. Liu K, Yu J, Russell DG. pckA-deficient Mycobacterium bovis BCG shows attenuated virulence in mice and in macrophages. Microbiology 2003; 149: 1829-35.